NCT01064648 2026-03-18
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT01364051 2026-03-18
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02893917 2026-03-18
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01116648 2026-03-05
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02345265 2026-03-05
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02446600 2026-03-05
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02502266 2026-03-05
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting